Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer
- 4 July 2014
- journal article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 2 (6) , 1103-1106
Abstract
Malignant ascites due to peritoneal metastasis is one of the major problems caused by advanced gastrointestinal cancer. Although drainage of a large amount of ascitic fluid improves symptoms such as abdominal fullness, it may lead to protein loss and renal dysfunction. Cell‑free and concentrated ascites reinfusion therapy (CART) may help avoid such complications due to paracentesis. The purpose of this study was to evaluate the safety of CART. We performed a total of 51 sessions of CART in 5 patients, 4 of whom had gastric cancer and 1 appendiceal cancer. We retrospectively evaluated laboratory data immediately prior to CART, on the following day, 1 week later and 2 weeks later. We also measured the amount of total protein and albumin in collected and concentrated ascites. The mean amount of collected ascites was 4,007 ml. All the patients exhibited improvement of symptoms such as abdominal fullness. Four patients developed fever (>38˚C) immediately after reinfusion of the concentrated ascites and 3 of these patients required corticosteroid administration. The mean total protein and albumin in the collected ascites were 122 and 64 g, respectively, and those in the concentrated ascites 75 and 39 g, respectively. The serum levels of total protein, albumin and creatinine after CART were almost identical to those prior to CART. Blood hemoglobin concentration was significantly decreased 1 day after CART and returned to baseline levels in 1‑2 weeks. CART does not cause renal dysfunction and does not decrease serum albumin; therefore, repeated CART is safe and may be used to improve the symptoms of malignant ascites from gastrointestinal cancer.Keywords
This publication has 12 references indexed in Scilit:
- Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer.2012
- A Case of Cell-Free and Concentrated Ascites Reinfusion Therapy Effective for Refractory Ascites in Spontaneous Bacterial Peritonitis in a Renal Transplant PatientCase Reports in Nephrology and Urology, 2012
- A Study of Appropriate Flow Rate Settings for Cell‐Free and Concentrated Ascites Reinfusion Therapy and Change of Cytokine Concentrations in AscitesTherapeutic Apheresis and Dialysis, 2011
- Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectivesInternational Journal of Clinical Oncology, 2011
- Treatment of Malignant AscitesCurrent Treatment Options in Oncology, 2008
- Reinfusion of Concentrated Ascitic Fluid versus Total Paracentesis (A Randomized Prospective Trial)Digestive Diseases and Sciences, 1997
- Prevention of the Febrile Reaction Occurring on Reinfusion of Cell-Free and Concentrated Autogenous Ascites.Japanese Journal of Medicine, 1991
- Changes in biochemical data in ascites and serum before and after the treatment of intractable ascites for patients with terminal gynecologic tumor: re-infusion of cell-free and concentrated ascitic fluid.1985
- [Treatment of intractable ascites at the terminal stage of ovarian carcinoma--reinfusion of the cell-free, concentrated ascitic fluid].1983
- A New Technique for Rapid Control of Cirrhotic AscitesArchives of Surgery, 1961